Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NMRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNeumora Therapeutics reports Q4 and full-year 2025 financial results
Filed March 30, 2026 · Period ending March 30, 2026 · ~1 min read
Key Changes
-
medium
Company announced fourth quarter and full-year 2025 financial results on March 30, 2026. Specific financial metrics and performance details are contained in the accompanying press release.
Item 2.02 verify on EDGAR → -
low
This is a routine quarterly earnings disclosure filing. The 8-K itself contains no financial details; all results are in the attached press release exhibit.
8-K: Earnings view on EDGAR →
Summary
Neumora Therapeutics filed an 8-K on March 30, 2026, announcing its fourth quarter and full-year 2025 financial results. This is a standard quarterly earnings disclosure required by SEC regulations. The filing itself is procedural and contains no financial details in the body text—all performance metrics, revenue figures, and management commentary are contained in the press release attached as an exhibit.
For retail investors, this represents routine financial reporting rather than a material corporate event. The actual substance of the company's financial performance, cash position, and operational updates would be found in the press release and any accompanying earnings call. Investors should review the full press release to understand Neumora's financial health, burn rate, and progress on clinical programs. Watch for any guidance updates or pipeline developments that may have been disclosed in the earnings materials.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 30, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2025.
The company disclosed its fourth quarter and full year 2025 financial results on March 30, 2026. The actual financial details are contained in the press release furnished as Exhibit 99.1, which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
Neumora filed an 8-K attaching a press release dated March 30, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release dated March 30, 2026
The 8-K references an attached press release dated March 30, 2026, but the filing body does not disclose the content or subject matter of that release. Without the exhibit text, the nature and materiality of the disclosed event cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify